Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMorote Robles, Joan
dc.contributor.authorBorque Fernando, Ángel
dc.contributor.authorTriquell Llauradó, Marina
dc.contributor.authorCelma Domènech, Anna
dc.contributor.authorRegis Plácido, Lucas
dc.contributor.authorMast, Richard
dc.contributor.authorTorres Ramirez, Inés de
dc.contributor.authorSemidey Raven, Maria Eugenia
dc.contributor.authorSantamaria Margalef, Anna
dc.contributor.authorPlanas Morin, Jacques
dc.contributor.authorTrilla Herrera, Enric
dc.date.accessioned2022-09-07T12:33:14Z
dc.date.available2022-09-07T12:33:14Z
dc.date.issued2022-05
dc.identifier.citationMorote J, Borque-Fernando A, Triquell M, Celma A, Regis L, Mast R, et al. Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy. Cancers. 2022 May;14(10):2374.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/8063
dc.descriptionClinically significant prostate cancer; Predictive model; Prostate-specific antigen
dc.description.abstractThis study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880–0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774–0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;14(10)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPròstata - Càncer - Imatgeria per ressonància magnètica
dc.subjectPròstata - Biòpsia
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshBiopsy
dc.subject.meshProstatic Neoplasms
dc.subject.mesh/diagnostic imaging
dc.titleComparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers14102374
dc.subject.decsimagen por resonancia magnética
dc.subject.decsbiopsia
dc.subject.decsneoplasias de la próstata
dc.subject.decs/diagnóstico por imagen
dc.relation.publishversionhttps://doi.org/10.3390/cancers14102374
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Morote J, Trilla E] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Borque-Fernando A] Department of Urology, Hospital Miguel Servet, IIS-Aragon, 50009 Zaragoza, Spain. [Triquell M, Celma A, Regis L, Planas J] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mast R] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [de Torres IM, Semidey ME] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Ciències Morfològiques, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Santamaría A] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid35625978
dc.identifier.wos000801886000001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01666
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record